Laurence Baker discloses that he chairs the career development committee of Sarcoma Alliance for Research through Collaboration (SARC) and has, as a faculty member of the University of Michigan, a conflict of interest management plan for his SARC activities. Section Editor Jaap Verweij discloses no financial relationships relevant to the content of this article. Reviewer "A" discloses honoraria received from Novartis and Pfizer, a consulting relationship with Merck, and institutional clinical research support from Novartis, ARIAD/Merck, and Ziopharm. Reviewer "B" discloses honoraria received from Novartis and Pfizer, and research funding from Novartis, Pfizer, and Roche. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. On the basis of disclosed information, all conflicts of interest have been resolved. LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Characterize and compare the clinical behavior and outcome of patients with epithelioid sarcoma and unclassified sarcoma with epithelioid features.2. Identify differentiation and other tumor-related molecular markers in human ES and USEF specimens described in this study.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTBackground. Epithelioid sarcoma (ES) and unclassified sarcoma with epithelioid features (USEF) are clinically

No abstract

No abstract